We have located links that may give you full text access.
Clinical parameters to optimize patient selection for subcutaneous and transvenous implantable defibrillator therapy.
Pacing and Clinical Electrophysiology : PACE 2018 June 14
BACKGROUND: The subcutaneous implantable cardioverter-defibrillator (S-ICD) lacks the antitachycardia pacing (ATP) capability of tranvenous ICDs (TV-ICD). S-ICD patient selection can be challenging as some patients may benefit from ATP. We aim to identify clinical predictors of ATP benefit, in order to improve patient selection for S-ICD or TV-ICD therapy.
METHODS: De novo single- and dual-chamber TV-ICD patients implanted between March 2011 and December 2015 were included. Ventricular arrhythmias terminated by ATP and not followed by a shock were considered successful ATP therapy. Cox proportional hazard analysis was performed to assess the adjusted effect of multiple predictors for appropriate ATP and shock therapy.
RESULTS: Note that 431 patients were included with a median follow-up of 26 months. Ninety-nine patients (23%) received appropriate ATP therapy, which terminated the arrhythmia in 67%. A history of nonsustained ventricular tachycardia (NSVT) or monomorphic VT (MVT) was the only predictor of appropriate ATP therapy in the multivariable model (hazard ratio [HR] 2.73, P < 0.001). Sixty-five of 221 patients with a history of NS (VT) received appropriate ATP (29%) versus 24 patients (11%) without a history NS (VT) (P < 0.001). A secondary prevention indication was the only predictor in the multivariate model for appropriate shock therapy (HR 1.82, P = 0.05).
CONCLUSION: A history of NSVT or MVT is a significant predictor for appropriate and successful ATP therapy. One in three patients with NSVT or MVT received appropriate ATP versus one in 10 patients without a history of NSVT or MVT over a 2-year period of follow-up.
METHODS: De novo single- and dual-chamber TV-ICD patients implanted between March 2011 and December 2015 were included. Ventricular arrhythmias terminated by ATP and not followed by a shock were considered successful ATP therapy. Cox proportional hazard analysis was performed to assess the adjusted effect of multiple predictors for appropriate ATP and shock therapy.
RESULTS: Note that 431 patients were included with a median follow-up of 26 months. Ninety-nine patients (23%) received appropriate ATP therapy, which terminated the arrhythmia in 67%. A history of nonsustained ventricular tachycardia (NSVT) or monomorphic VT (MVT) was the only predictor of appropriate ATP therapy in the multivariable model (hazard ratio [HR] 2.73, P < 0.001). Sixty-five of 221 patients with a history of NS (VT) received appropriate ATP (29%) versus 24 patients (11%) without a history NS (VT) (P < 0.001). A secondary prevention indication was the only predictor in the multivariate model for appropriate shock therapy (HR 1.82, P = 0.05).
CONCLUSION: A history of NSVT or MVT is a significant predictor for appropriate and successful ATP therapy. One in three patients with NSVT or MVT received appropriate ATP versus one in 10 patients without a history of NSVT or MVT over a 2-year period of follow-up.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app